Japan’s Takeda Sees $725 Million in Costs From R&D Revamp

Takeda Pharmaceutical Co. said efforts to revamp its research operations will cost 75 billion yen ($725 million) as it seeks to build a new pipeline of drugs and considers closing some R&D operations in the U.K.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.